RESUMO
AIM: To evaluate the clinical efficacy and tolerability of etoricoxib and meloxicam in patients with gonarthrosis. SUBJECTS AND METHODS: A postregistration, open-labeled, prospective, comparative randomized study was conducted. 40 patients aged 37 to 75 years with primary knee osteoarthritis were examined. Therapeutic effectiveness was evaluated determining the functional index WOMAC with the use of a visual analogue scale (VAS). The tolerability of the drugs was assessed according to the opinions of a patient and a physician. RESULTS: Both drugs caused a reduction in WOMAC and VAS scores for pain and the severity of the disease. Etoricoxib demonstrated a significantly high rate of occurrence and completeness of its analgesic effect. Meloxicam showed a less pronounced decrease in joint stiffness and an insufficient analgesic effect. The incidence of side effects was similar in both groups. CONCLUSION: Both drugs demonstrated a good tolerability and a low incidence of side effects. The efficacy of etoricoxib was significantly higher than that of meloxicam.
Assuntos
Osteoartrite , Piridinas , Sulfonas , Tiazinas , Tiazóis , Adulto , Idoso , Inibidores de Ciclo-Oxigenase/administração & dosagem , Inibidores de Ciclo-Oxigenase/efeitos adversos , Monitoramento de Medicamentos/métodos , Etoricoxib , Feminino , Humanos , Masculino , Meloxicam , Pessoa de Meia-Idade , Osteoartrite/diagnóstico , Osteoartrite/tratamento farmacológico , Medição da Dor/métodos , Gravidade do Paciente , Piridinas/administração & dosagem , Piridinas/efeitos adversos , Sulfonas/administração & dosagem , Sulfonas/efeitos adversos , Tiazinas/administração & dosagem , Tiazinas/efeitos adversos , Tiazóis/administração & dosagem , Tiazóis/efeitos adversos , Resultado do TratamentoRESUMO
It is shown that metformin, which is a drug used for treatment of type 2 diabetes mellitus, metabolizes itself in vivo in the intestine and liver of mice with the release of nitric oxide. Subsequently the released nitric oxide forms paramagnetic mono- and dinitrosyl iron complexes which can be registered by EPR method. It is suggested that nitric oxide is just responsible for multifarious therapeutic action of metformin such as lowering of blood glucose level, reduction of arterial hypertension and other biological effects.
Assuntos
Hipoglicemiantes/farmacocinética , Ferro/sangue , Metformina/farmacocinética , Doadores de Óxido Nítrico/farmacocinética , Óxido Nítrico/sangue , Óxidos de Nitrogênio/sangue , Animais , Glicemia/metabolismo , Diabetes Mellitus Tipo 2/sangue , Diabetes Mellitus Tipo 2/tratamento farmacológico , Espectroscopia de Ressonância de Spin Eletrônica , Humanos , Hipertensão/sangue , Hipertensão/tratamento farmacológico , Hipoglicemiantes/farmacologia , Metformina/farmacologia , Camundongos , Doadores de Óxido Nítrico/farmacologiaRESUMO
Combined treatment including alpha-1a-adrenoreceptor blocker tamsulosine was given to 92 patients with chronic prostatitis having marked urination disorders (IPSS score 12.1 +/- 2.4). The response was achieved in 98.9% of cases. There was attenuation of the urination symptoms, speeding up of the maximal urine flow, decreased amount of the residual urine. It is recommended to add alpha-1-adrenoreceptors to combined treatment of chronic prostatitis patients with urination disorders.